The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

NCT04830267 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Camrelizumab
RADIATION: Stereotactic body radiotherapy

Sponsor

Chongqing University Cancer Hospital